Speaker Profile

Ph.D., Co-founder and Chief Strategy Officer, Genetika+

Genetika+ is focused on personalizing treatment in the mental health space, with a first product focusing on optimizing drug choice in depression. Prior to co-founding Genetika+ , Daphna was Chief Scientific Officer at Ibex Medical Analytics, a digital health company developing AI-based cancer diagnostics, and before that, she served as Head, Personalized Medicine and Diagnostics at Teva Pharmaceuticals, where she supported the discovery, development and differentiation of Teva’s pipeline drugs, in collaboration with the Israeli healthcare sector and multinational companies. Daphna joined Teva after having led biomarker and diagnostic development activities within the pipeline of multiple top-10 pharma and fortune 500 companies. She served in several roles with increasing responsibility at Selventa, a system's biology company focused on personalized medicine, and founded the Israeli branch of the company, as Global Head of Diagnostics. Daphna trained as post-doc at Harvard University, after receiving her PhD in Medical Sciences from the Technion.

Clinical Dx Showcase:

Genetika+ personalizes treatment in the mental health space, initially focusing on depression. The Genetika+ platform uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Brain in a Dish: Personalizing Treatment in Depression
Major depression is a leading cause of health-related burden globally, further exacerbated by Covid-19. Despite the availability of many antidepressant on the market, most patients do not effectively respond to the prescribed treatment. Genetika+’s RxMine platform converts patients' blood cells into neurons, which in turn are used to screen for the optimal drug for each individual. By combining the patient’s genetics and medical history into an AI-based algorithm, a tailored report describes the optimal drug for each patient.

 Session Abstract – PMWC 2022 Silicon Valley

Track 6 - June 28 9.00 A.M.-4.45 P.M.,Track 6 - June 29 3.30 P.M.-3.45 P.M.,Track 6 - June 30 9.00 A.M.-1.15 P.M.

The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative


Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by AUG. 1ST

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts

Contact Us:

Fields marked with an * are required 

Discount also depends on group size. The bigger group – the bigger discount.

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required